Abstract 2128P
Background
Exercise (EX) is associated with a reduction in mortality and recurrence risk in patients (pts) with cancer and may help pts cope with treatment side effects and improve their quality of life. This study aims to explore the role of oncologists in promoting exercise in the oncological context.
Methods
A self-administered, anonymous questionnaire was proposed to pts visiting the outpatients’ facilities at the Oncology Unit of Verona Hospital. The questionnaire assessed demographic, health, and EX parameters. EX variables, drawn from a prior study, included: the level evaluated with Godin’s Leisure Time Exercise Questionnaire and information regarding: whether EX was discussed; whether oncologists assess, advise, reinforce, and refer (AARR process) pts effort to exercising; and whether pts preferred that EX be discussed. Descriptive statistic, presented as mean, frequencies, and percentages, was applied.
Results
Overall, 202 pts completed the survey (76% response rate). The most frequent tumor types were upper gastrointestinal (45%) and breast (19%). Only 9% of pts were sufficiently active. Regarding the actual EX discussion, 29% of pts reported that their oncologist started a discussion about EX, 12% initiated the discussion themselves, and 60% referred that the issue was not considered. Concerning the AARR process, 26% of pts declared that their oncologists assessed their EX level, 14% and 33% received advice or reinforcement to increase their EX, respectively, and 9% were referred to an appropriate EX service. On the other hand, the items related to the preferred modality of EX discussion showed that 69% of pts thought that oncologists should initiate an EX-discussion, 3% that only pts should start the discussion, and 23% thought that EX should not be discussed.
Conclusions
Our preliminary results show that most pts are insufficiently active, and the majority stated that they did not discuss EX. Nevertheless, most pts would prefer that oncologists initiate a discussion about EX. According to these findings, strategies to support clinicians in promoting EX to their pts should be developed. Further pts’ enrollment is currently ongoing and a more updated analysis will be available for presentation at the ESMO Congress.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06
2086P - Management of opioids use disorder in cancer survivors
Presenter: Khalida Berkane
Session: Poster session 06
2087P - Impact of cancer pain on quality of life and financial well-being: A cross-sectional study on symptom management
Presenter: Raffaele Giusti
Session: Poster session 06
2088P - Management of cancer treatment-induced bone loss in patients with breast and hormone sensitive prostate cancer: AIOM survey among Italian oncologists
Presenter: Anna Amela Valsecchi
Session: Poster session 06
2090P - Management of trastuzumab deruxtecan-related nausea and vomiting in real-world practice
Presenter: Luca Licata
Session: Poster session 06
2091P - Dermocosmetics in management of cancer-related skin toxicities: International expert consensus highlighting the key role of oncology nurses
Presenter: Pascale Dielenseger
Session: Poster session 06
2092P - Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors
Presenter: MACHEROUM Fatma zohra
Session: Poster session 06
2093P - Bioelectrical Impedance phase angle and obesity as a prognostic indicator in metastatic gastric cancer patients receiving second-line chemotherapy
Presenter: SangUk Han
Session: Poster session 06
2094P - A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer
Presenter: Shinya Takada
Session: Poster session 06